Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections, today …
Newly discovered antibiotic binds to ribosomeand disrupts protein synthesis Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University …
Symcel, the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™, has secured €3.572 million Horizon 2020 funding to support the …
Locus Biosciences has closed $19 million in Series A funding led by venture capital firm ARTIS Ventures with additional financing from notable institutional investors Tencent …
In 2017, the collective fight to combat antimicrobial resistance (AMR) has experienced a new upswing. Following the eye-opening report of British economist Lord Jim O’Neill, …
Helperby Therapeutics (Helperby), a pioneering British biopharmaceuticals company, have developed a novel answer to the clear and present danger of antimicrobial resistance – Antibiotic Resistance …
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative
